Vaccine Advisory Panels Delay Decisions on Hepatitis B and COVID Shots, Raising Concerns

A U.S. federal vaccine advisory panel is debating delaying the hepatitis B vaccine for newborns, which could risk a resurgence of the disease, despite longstanding public health success. The delay is being considered for babies born to hepatitis B-negative mothers, but experts warn it could lead to more cases of chronic liver disease. The panel also discussed separating the MMRV vaccine doses, which has caused controversy and confusion about vaccination practices. The decisions reflect ongoing debates about vaccine safety, trust, and public health policy.